Gritstone bio Inc
NASDAQ:GRTS
Gritstone bio Inc
Revenue
Gritstone bio Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Gritstone bio Inc
NASDAQ:GRTS
|
Revenue
$16.3m
|
CAGR 3-Years
59%
|
CAGR 5-Years
69%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Gritstone bio Inc
Revenue Breakdown
Breakdown by Geography
Gritstone bio Inc
Breakdown by Segments
Gritstone bio Inc
Total Revenue:
16.3m
USD
|
Grant:
15m
USD
|
License:
1.3m
USD
|
Collaboration Revenue:
300k
USD
|
See Also
What is Gritstone bio Inc's Revenue?
Revenue
16.3m
USD
Based on the financial report for Dec 31, 2023, Gritstone bio Inc's Revenue amounts to 16.3m USD.
What is Gritstone bio Inc's Revenue growth rate?
Revenue CAGR 5Y
69%
Over the last year, the Revenue growth was -18%. The average annual Revenue growth rates for Gritstone bio Inc have been 59% over the past three years , 69% over the past five years .